Idioma:

Genomic profiling for clinical decision making in lymphoid neoplasms

de Leval, Laurence ; Alizadeh, Ash A. ; Bergsagel, P. Leif ; Campo, Elias ; Davies, Andrew ; Dogan, Ahmet ; Fitzgibbon, Jude ; Horwitz, Steven M. ; Melnick, Ari M. ; Morice, William G. ; Morin, Ryan D. ; Nadel, Bertrand ; Pileri, Stefano A. ; Rosenquist, Richard ; Rossi, Davide ; Salaverria, Itziar ; Steidl, Christian ; Treon, Steven P. ; Zelenetz, Andrew D. ; Advani, Ranjana H. ; Allen, Carl E. ; Ansell, Stephen M. ; Chan, Wing C. ; Cook, James R. ; Cook, Lucy B. ; d’Amore, Francesco ; Dirnhofer, Stefan ; Dreyling, Martin ; Dunleavy, Kieron ; Feldman, Andrew L. ; Fend, Falko ; Gaulard, Philippe ; Ghia, Paolo ; Gribben, John G. ; Hermine, Olivier ; Hodson, Daniel J. ; Hsi, Eric D. ; Inghirami, Giorgio ; Jaffe, Elaine S. ; Karube, Kennosuke ; Kataoka, Keisuke ; Klapper, Wolfram ; Kim, Won Seog ; King, Rebecca L. ; Ko, Young H. ; LaCasce, Ann S. ; Lenz, Georg ; Martin-Subero, José I. ; Piris, Miguel A. ; Pittaluga, Stefania ; Pasqualucci, Laura ; Quintanilla-Martinez, Leticia ; Rodig, Scott J. ; Rosenwald, Andreas ; Salles, Gilles A. ; San-Miguel, Jesus ; Savage, Kerry J. ; Sehn, Laurie H. ; Semenzato, Gianpietro ; Staudt, Louis M. ; Swerdlow, Steven H. ; Tam, Constantine S. ; Trotman, Judith ; Vose, Julie M. ; Weigert, Oliver ; Wilson, Wyndham H. ; Winter, Jane N. ; Wu, Catherine J. ; Zinzani, Pier L. ; Zucca, Emanuele ; Bagg, Adam ; Scott, David W.

Blood, 2022-11, Vol.140 (21), p.2193-2227 [Periódico revisado por pares]

United States: Elsevier Inc

Texto completo disponível

Citações Citado por

Enviar para

Título:
Genomic profiling for clinical decision making in lymphoid neoplasms
Autor: de Leval, Laurence ; Alizadeh, Ash A. ; Bergsagel, P. Leif ; Campo, Elias ; Davies, Andrew ; Dogan, Ahmet ; Fitzgibbon, Jude ; Horwitz, Steven M. ; Melnick, Ari M. ; Morice, William G. ; Morin, Ryan D. ; Nadel, Bertrand ; Pileri, Stefano A. ; Rosenquist, Richard ; Rossi, Davide ; Salaverria, Itziar ; Steidl, Christian ; Treon, Steven P. ; Zelenetz, Andrew D. ; Advani, Ranjana H. ; Allen, Carl E. ; Ansell, Stephen M. ; Chan, Wing C. ; Cook, James R. ; Cook, Lucy B. ; d’Amore, Francesco ; Dirnhofer, Stefan ; Dreyling, Martin ; Dunleavy, Kieron ; Feldman, Andrew L. ; Fend, Falko ; Gaulard, Philippe ; Ghia, Paolo ; Gribben, John G. ; Hermine, Olivier ; Hodson, Daniel J. ; Hsi, Eric D. ; Inghirami, Giorgio ; Jaffe, Elaine S. ; Karube, Kennosuke ; Kataoka, Keisuke ; Klapper, Wolfram ; Kim, Won Seog ; King, Rebecca L. ; Ko, Young H. ; LaCasce, Ann S. ; Lenz, Georg ; Martin-Subero, José I. ; Piris, Miguel A. ; Pittaluga, Stefania ; Pasqualucci, Laura ; Quintanilla-Martinez, Leticia ; Rodig, Scott J. ; Rosenwald, Andreas ; Salles, Gilles A. ; San-Miguel, Jesus ; Savage, Kerry J. ; Sehn, Laurie H. ; Semenzato, Gianpietro ; Staudt, Louis M. ; Swerdlow, Steven H. ; Tam, Constantine S. ; Trotman, Judith ; Vose, Julie M. ; Weigert, Oliver ; Wilson, Wyndham H. ; Winter, Jane N. ; Wu, Catherine J. ; Zinzani, Pier L. ; Zucca, Emanuele ; Bagg, Adam ; Scott, David W.
Assuntos: Clinical Decision-Making ; Genomics - methods ; High-Throughput Nucleotide Sequencing ; Humans ; Lymphoma - diagnosis ; Lymphoma - genetics ; Lymphoma - therapy ; Medicin och hälsovetenskap ; Neoplasms ; Precision Medicine
É parte de: Blood, 2022-11, Vol.140 (21), p.2193-2227
Notas: ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Descrição: With the introduction of large-scale molecular profiling methods and high-throughput sequencing technologies, the genomic features of most lymphoid neoplasms have been characterized at an unprecedented scale. Although the principles for the classification and diagnosis of these disorders, founded on a multidimensional definition of disease entities, have been consolidated over the past 25 years, novel genomic data have markedly enhanced our understanding of lymphomagenesis and enriched the description of disease entities at the molecular level. Yet, the current diagnosis of lymphoid tumors is largely based on morphological assessment and immunophenotyping, with only few entities being defined by genomic criteria. This paper, which accompanies the International Consensus Classification of mature lymphoid neoplasms, will address how established assays and newly developed technologies for molecular testing already complement clinical diagnoses and provide a novel lens on disease classification. More specifically, their contributions to diagnosis refinement, risk stratification, and therapy prediction will be considered for the main categories of lymphoid neoplasms. The potential of whole-genome sequencing, circulating tumor DNA analyses, single-cell analyses, and epigenetic profiling will be discussed because these will likely become important future tools for implementing precision medicine approaches in clinical decision making for patients with lymphoid malignancies. Complementing the recently published Blood articles outlining the 2022 International Consensus Classifications for hematological malignancies (Vol. 140, Issue 11), this pair of Special Reports illustrates how molecular pathology can be applied to precision medicine. de Leval and colleagues summarize the potential of DNA sequencing of tumors and cell-free plasma, epigenetic profiling, and single-cell analyses to inform clinical decision-making about diagnosis, prognosis, and treatment for patients with lymphoid neoplasms. Similarly, Duncavage and colleagues cover genomic profiling for myeloid neoplasms and the acute leukemias, focusing principally on somatic changes but also with emphasis on the emerging importance of germline gene mutations in certain diseases. Both articles provide up-to-date references for how to apply genomic information to practice.
Editor: United States: Elsevier Inc
Idioma: Inglês

Links

Voltar para lista de resultados

Realização: Logos de Redes Sociais:

Genomic profiling for clinical decision making in lymphoid neoplasms

United States: Elsevier Inc

Buscando em bases de dados remotas. Favor aguardar.